Total Funding
33
Total FundingGrant raised
Growth Score
pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
87156
Inflazome is a biotech company that develops orally available drugs to address inflammatory diseases by targeting inflammasomes.
Luke O'Neill: CEO & Chief Scientific Officer
About the Company
Inflazome is a biotech company that develops orally available drugs to address inflammatory diseases by targeting inflammasomes.
The company's drugs block inflammasome signals, eliminating a root cause of inflammation, enabling healthcare institutions to avail targeted therapies for inflammatory diseases such as Parkinson's,
Alzheimer's, atherosclerosis, and type 2 diabetes.
The company was incorporated in 2016 and is headquartered in Dublin, Ireland.
